DiaCarta, an innovative translational genomics and precision molecular diagnostics company, today announced that DiaCarta Clinical Services Laboratory (DCSL) successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
The State of California inspector gave DCSL permission to begin offering QClamp-based molecular diagnostic patient and clinical trial testing services.
The DiaCarta-owned and operated laboratories, both in Richmond, California (JOINN Innovation Park), and Nanjing, China, enable clinical and research laboratories, as well as diagnostic and pharmaceutical companies, to incorporate complex molecular tests into clinical practice.
The CLIA certification ensures that all of its processes are standardized to consistently meet federal and Clinical Laboratory Standards Institute (CLSI) guidelines for accuracy, precision, sensitivity, calibration and control. In addition, all of the DCSL assays have been validated for clinical applications to ensure reproducible results.
- Aiguo Zhang
- March 28, 2016
- CLIA Lab, Companion-Diagnostics, QClamp